Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature

Transplant Infectious Disease

Volumn 20, Issue 2, 2018, Pages

  Trang, Tracy P ^a   Whalen, Meghan ^b   Hilts Horeczko, Alexandra ^b,c   Doernberg, Sarah B ^d   Liu, Catherine ^e,f  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e USA   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

aerosolized; immunocompromised; oral; respiratory syncytial virus; ribavirin

Indexed keywords

RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; AEROSOL; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONCURRENT INFECTION; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOCOMPROMISED PATIENT; INTENSIVE CARE UNIT; LABORATORY TEST; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; LUNG INFILTRATE; LUNG LAVAGE; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RHINORRHEA; SINUS CONGESTION; SORE THROAT; THORAX RADIOGRAPHY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; DRUG ADMINISTRATION ROUTE; LUNG TRANSPLANTATION;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION ROUTES; HUMANS; LUNG TRANSPLANTATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 85044614387     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12844     Document Type: Article

References (29)

1. Neemann K, Freifeld A. Respiratory syncytial virus in hematopoietic stem cell transplantation and solid-organ transplant. Curr Infect Dis Rep. 2015;17:490.
2. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031.
3. Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178:876.
4. Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoetic cell transplantation: The role of community respiratory viruses. J Infect Dis. 2006;193:1619.
5. Avetisyan G, Mattsson J, Sparrelid E, et al. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: A retrospective study of the incidence, clinical features, and outcome. Transplantation. 2009;88:1222-1226.
6. McCarthy AJ, Kingman HM, Kelly C, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogenic stem cell transplantation. Bone Marrow Transplant. 1999;24:1315-1322.
7. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992;165:987-993.
8. Lewinsohn DM, Bowden RA, Mattson D, et al. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother. 1996;40:2555-2557.
9. Machado CM, Boas LS, Mendes AV, et al. Low morality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 2003;31:695-700.
10. Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28:67-71.
11. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983;308:1443-1447.
12. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogenic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68:1872-1880.
13. Schiffer JT, Kirby K, Sandmaier B, et al. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94:1101-1108.
14. Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012;46:558-566.
15. Chemaly RF, Aitken SL, Wolfe CR, et al. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18:634-646.
16. Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: A survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016;18:210-215.
17. Marcelin JR, Wilson JW, Razonable RR. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis. 2014;16:242-250.
18. Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency. J Heart Lung Transplant. 2015;34:958-962.
19. Li L, Avery R, Budev M, et al. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31:839-844.
20. Mori T, Nakamura Y, Kato J, et al. Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2011;93:132-134.
21. Gueller S, Buenzinger U, Wolf T, et al. Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2013;15:435-440.
22. Lehners N, Schnitzler P, Geis S, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant. 2013;48:1548-1553.
23. Khanna N, Widmer A, Decker M, et al. Respiratory syncytial virus infection in patients with hematological disease: Single-centre study and review of the literature. Clin Infect Dis. 2008;46:402-412.
24. Anak S, Atay D, Unuvar A, et al. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. Pediatr Pulmonol. 2010;45:307-311.
25. Gorcea CM, Tholouli E, Turner A, et al. Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients. J Hosp Infect. 2017;95:214-217.
26. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infection. Blood. 2014;123:3263-3268.
27. Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010;12:38-44.
28. Fuehner T, Dierich M, Duesberg C, et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther. 2011;16:733-740.
29. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117:2755-2763.